Resverlogix

Organisation

Trials

  • NCT02586155

    Phase 3, Completed, 2,425 people, 26 Oct 2015

  • NCT01863225

    Phase 2, Terminated, 13 people, 27 May 2013

Named in competing interests

Sources: pubmed.ncbi.nlm.nih.gov